Mandate

Vinge advises Capillar in connection with Sweden’s first ever de-SPAC

Capillar and the minority shareholders have entered into an agreement to sell all shares in Spolargruppen Sverige AB, a Swedish leading player in pipe lining (so-called relining) and pipe flushing, to tbd30 AB (publ), a so called SPAC (Special Purpose Acquisition Company).

In connection with the proposed transaction, a process is initiated (so-called “de-SPAC” or company combination) which includes, among other things, that Nasdaq Stockholm AB examines the intended acquisition, application for listing and change of trading venue to Nasdaq First North Growth Market within the framework of Nasdaq Stockholm's regulations regarding SPACs.

As part of the continued financing, a number of institutional and other investors, including Lannebo Fonder and Carnegie Fonder, have undertaken to subscribe for 1,500,000 new class A shares in tbd30 in a directed new share issue at SEK 100 per share.

Vinges team primarily consists of Christina Kokko, Joacim Rydergård, Hannah Kajlinger and Philip Moré (M&A), Linnéa Sellström (Equity Capital Markets) as well as Matthias Schömer and Henrik Wastenson (Tax).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025